This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pharmacology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • bupropion was developed originally as an antidepressant - it is structurally similar to diethylpropion (an appetite suppressant)

  • in vitro studies suggest that bupropion is a weak inhibitor of re-uptake of dopamine and noradrenaline; also in vitro studies suggest that bupropion is, in addition, a much weaker inhibitor of serotonin re-uptake. Bupropion does not inhibit monoamine oxidase (1)

  • other in vitro studies suggest that bupropion acts as a non-competitive antagonist at nicotine acetylcholine receptors (2)

  • bupropion has a half-life of about 20 hours; steady-state plasma concentrations of bupropion and its metabolites occur within 8 days

Reference:

  • 1) Ascher JA et al (1995). Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry, 56, 395-401.
  • 2) Fryer JD, Lukas RJ (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther, 288, 88-92.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.